Prostate Cancer
Globally, prostate cancer (PCa) is the second most common cancer to affect males. Tumors vary in their level of aggression; non-aggressive tumors can be safely monitored, while tumors with a poor prognosis are only appropriate for palliative care. Modern imaging, biomarkers, nomograms, and accurate...
Պահպանված է:
| Ձևաչափ: | Online |
|---|---|
| Լեզու: | անգլերեն |
| Հրապարակվել է: |
MDPI - Multidisciplinary Digital Publishing Institute
2025
|
| Խորագրեր: | |
| Առցանց հասանելիություն: | ONIX_20250812T110751_9783725842957_418 |
| Ցուցիչներ: |
Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!
|
| _version_ | 1869521940121649152 |
|---|---|
| collection | Directory of Open Access Books |
| description | Globally, prostate cancer (PCa) is the second most common cancer to affect males. Tumors vary in their level of aggression; non-aggressive tumors can be safely monitored, while tumors with a poor prognosis are only appropriate for palliative care. Modern imaging, biomarkers, nomograms, and accurate stratification—especially for the most clinically diverse subset of intermediate-risk patients—offer a more effective framework for managing these individuals. Because regular transrectal ultrasound is not always accurate, targeted biopsies improve the detection of clinically significant PCa. Magnetic resonance imaging (MRI) is essential for local staging and can help determine when a prostate biopsy is indicated. Modern, less costly ultrasound-based techniques offer high-quality imaging when MRI is not possible. For the staging of aggressive tumors, more accurate staging techniques, such as PSMA PET/CT, have been employed; however, at this time, there is insufficient information to justify further care. Germline testing and genetic counseling can aid in the early detection and treatment of PCa. Urine, serum, and tissue-based biomarkers enhance the detection and facilitate risk classification for patients with PCa. Together, these methods produce risk calculators and nomograms that can be used to predict the risk of cancer, the likelihood of aggressive disease, and the probability of a positive treatment response. This reprint aims to provide new insights into PCa, and the advances in diagnostics and treatment planning. |
| format | Online |
| id | doab-20.500.12854ir-165663 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2025 |
| publishDateRange | 2025 |
| publishDateSort | 2025 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1656632025-08-12T10:04:53Z Prostate Cancer Tokas, Theodoros prostate cancer prostate biopsy prostate imaging ultrasound magnetic resonance imaging MRI PET scan biomarkers nomograms thema EDItEUR::M Medicine and Nursing Globally, prostate cancer (PCa) is the second most common cancer to affect males. Tumors vary in their level of aggression; non-aggressive tumors can be safely monitored, while tumors with a poor prognosis are only appropriate for palliative care. Modern imaging, biomarkers, nomograms, and accurate stratification—especially for the most clinically diverse subset of intermediate-risk patients—offer a more effective framework for managing these individuals. Because regular transrectal ultrasound is not always accurate, targeted biopsies improve the detection of clinically significant PCa. Magnetic resonance imaging (MRI) is essential for local staging and can help determine when a prostate biopsy is indicated. Modern, less costly ultrasound-based techniques offer high-quality imaging when MRI is not possible. For the staging of aggressive tumors, more accurate staging techniques, such as PSMA PET/CT, have been employed; however, at this time, there is insufficient information to justify further care. Germline testing and genetic counseling can aid in the early detection and treatment of PCa. Urine, serum, and tissue-based biomarkers enhance the detection and facilitate risk classification for patients with PCa. Together, these methods produce risk calculators and nomograms that can be used to predict the risk of cancer, the likelihood of aggressive disease, and the probability of a positive treatment response. This reprint aims to provide new insights into PCa, and the advances in diagnostics and treatment planning. 2025-08-12T10:04:51Z 2025-08-12T10:04:51Z 2025 book ONIX_20250812T110751_9783725842957_418 9783725842957 9783725842964 https://directory.doabooks.org/handle/20.500.12854/165663 eng image/jpeg Attribution 4.0 International https://mdpi.com/books https://mdpi.com/books/pdfview/book/11151 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-4296-4 10.3390/books978-3-7258-4296-4 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725842957 9783725842964 108 open access |
| spellingShingle | prostate cancer prostate biopsy prostate imaging ultrasound magnetic resonance imaging MRI PET scan biomarkers nomograms thema EDItEUR::M Medicine and Nursing Prostate Cancer |
| title | Prostate Cancer |
| title_full | Prostate Cancer |
| title_fullStr | Prostate Cancer |
| title_full_unstemmed | Prostate Cancer |
| title_short | Prostate Cancer |
| title_sort | prostate cancer |
| topic | prostate cancer prostate biopsy prostate imaging ultrasound magnetic resonance imaging MRI PET scan biomarkers nomograms thema EDItEUR::M Medicine and Nursing |
| topic_facet | prostate cancer prostate biopsy prostate imaging ultrasound magnetic resonance imaging MRI PET scan biomarkers nomograms thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20250812T110751_9783725842957_418 |